Amphotericin B and its delivery by liposomal and lipid formulations
Journal of Clinical Pharmacy and TherapeuticsPublished 1 June 1993
Cynthia A. Gates, R. J. Pinney
Citations69
SJR quartileQ3
SJR score0.58
SNIP0.74
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
In recent years, new formulations of the original amphotericin B preparation (Fungizone) have been devised in order to overcome toxicity problems that frequently occur, and they represent an improved method of drug delivery, with an increased therapeutic index and a decrease in toxicity to mammalian cell membranes.
Abstract
In recent years, new formulations of the original amphotericin B preparation (Fungizone) have been devised in order to overcome toxicity problems that frequently occur. These preparations represent an improved method of drug delivery, with an increased therapeutic index and a decrease in toxicity to mammalian cell membranes. The new formulations have different physico-chemical characteristics and differ in pharmacokinetic parameters. Their effects must be compared with conventional amphotericin B to ascertain potential roles in future antifungal therapy.
Keywords
Agricultural and Biological SciencesChemistryMedicine
American Journal of Health-System PharmacyAmerican Journal of Hospital Pharmacy
942 Citations1958Don E. Francke
New England Journal of MedicineA Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis
862 Citations1979John E. Bennett, William E. Dismukes +13 more
It is concluded that combined flucytosine-amphoericin B therapy is the regimen of choice in cryptococcal meningitis.
Biochimica et Biophysica Acta (BBA) - Reviews on BiomembranesHow do the polyene macrolide antibiotics affect the cellular membrane properties?
752 Citations1986Jacques Bolard
Although pore formation is apparently involved in the toxicity of amphotericin B and nystatin, it is not the sole factor which contributes to cell death, since K+ leakage induced by these antibiotics is separate from their lethal action.
New England Journal of MedicineTreatment of Cryptococcal Meningitis with Combination Amphotericin B and Flucytosine for Four as Compared with Six Weeks
415 Citations1987William E. Dismukes, Gretchen A. Cloud +14 more
The view is that the four-week regimen should be reserved for patients who have meningitis without neurologic complications, underlying disease, or immunosuppressive therapy; a pretreatment cerebrospinal fluid white-cell count above 20 per cubic millimeter and a serum cryptococcal antigen titer below 1:32.
The Journal of Infectious DiseasesLiposomal Amphotericin B for the Treatment of Systemic Fungal Infections in Patients with Cancer: A Preliminary Study
408 Citations1985G. Lopez‐Berestein, Victor Fainstein +11 more
Twelve patients with hematologic malignancies complicated by fungal infections were treated with liposomal amphotericin B (L-AmpB); nine patients were granulocytopenic; the three additional patients with normal granulocyte counts were immunosuppressed.
The Journal of Infectious DiseasesTreatment and Prophylaxis of Disseminated Infection Due to Candida albicans in Mice with Liposome-Encapsulated Amphotericin B
301 Citations1983Gabriel Lopez‐Berestein, R T Mehta +8 more
The encapsulated drug was as effective as the free drug when used in similar concentrations, while the animals treated with higher concentrations of liposomal amphotericin B had a longer survival time and an improved therapeutic index resulted by encapsulating amph esotericin B in liposomes.
Journal of Antimicrobial ChemotherapyEfficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients
281 Citations1991Olle Ringdén, F. Meunier +10 more
It is concluded that AmBisome is an effective antifungal agent in a majority of patients with invasive or superficial fungal infections.
The Journal of Infectious DiseasesAmphotericin B-Induced Oxidative Damage and Killing of Candida albicans
281 Citations1986Marcia L. Sokol-Anderson, J Brajtburg +1 more
The lethal and lytic effects of AmB on C. albicans cells and protoplasts, but not prelethal AmB-induced K+ leakage, are mediated by oxidative damage.
Clinical PharmacokineticsLiposomal and Lipid Formulations of Amphotericin B
273 Citations1992Robert Janknegt, Siem de Marie +2 more
Antimicrobial Agents and ChemotherapyAmphotericin B Pharmacokinetics in Humans
268 Citations1978Arthur J. Atkinson, John E. Bennett
The pharmacokinetics of amphotericin B were studied in two patients at the conclusion of long-term therapy for disseminated histoplasmosis and the distribution kinetics were adequately described by a three-compartment mamillary model with a total distribution volume averaging 4 liters/kg.
Journal of Antimicrobial ChemotherapyLiposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial
248 Citations1991F. Meunier, H. G. Prentice +1 more
The analysis of safety data provided in a multicentre compassionate phase II/III study evaluating 133 episodes of therapy with AmBisome in patients with severe underlying disease is very encouraging, and its efficacy should be further investigated.
Biochimica et Biophysica Acta (BBA) - General SubjectsDisintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins
247 Citations1978Gerrit L. Scherphof, Frits H. Roerdink +2 more
Massive release of entrapped 125I-labeled albumin from the liposome during incubation with plasma suggests that the observed release of phosphatidylcholine from theliposomes has a highly destructive influence on the Liposomal structure.
The Annual Review of Pharmacology and ToxicologyAntifungal Agents Useful in Therapy of Systemic Fungal Infections
236 Citations1983Gerald Medoff, J Brajtburg +2 more
Journal of Clinical OncologyTreatment of hepatosplenic candidiasis with liposomal-amphotericin B.
216 Citations1987Gabriel Lopez‐Berestein, Gerald P. Bodey +2 more
Archives of Internal MedicinePrevention of Amphotericin B—Induced Renal Impairment
195 Citations1988Robert A. Branch
Mounting clinical evidence supports the usefulness of sodium supplementation to prevent as well as to reverse amphotericin B-induced nephrotoxicity, and preliminary observations merit confirmation in a prospective, randomized clinical trial.
Clinical PharmacokineticsClinical Pharmacokinetics of Systemic Antifungal Drugs
182 Citations1983Tawfique K. Daneshmend, David W. Warnock
The currently available drugs for the treatment of systemic fungal infections are amphotericin B, flucytosine, miconazole and ketoconazole, all of which have to be given intravenously for treatment of deep mycoses.
American Journal of Health-System PharmacyUse of liposomes as injectable-drug delivery systems
178 Citations1989Marc J. Ostro, Pieter R. Cullis
Liposomal encapsulation of drugs represents a new drug delivery system that appears to offer important therapeutic advantages over existing methods of drug delivery and is likely to receive approval for marketing in the early 1990s.
Antimicrobial Agents and ChemotherapyAmphotericin B lipid complex therapy of experimental fungal infections in mice
159 Citations1991Junius M. Clark, R R Whitney +5 more
ABLC, with its reduced toxicity, could be administered at drug levels capable of giving a therapeutic response, and should be of value in the treatment of severe fungal infections in humans.
Journal of Pharmacy and PharmacologyPharmaceutical Technology
145 Citations2006Darragh Murnane, Graham Martin +1 more
It is concluded that film formulations gave prolonged release with films remaining intact up to 4 h, which might be advantageous for periodontal therapy in future with lower concentrations of antimicrobial agents.
Journal of Antimicrobial ChemotherapyOverview of liposomes
126 Citations1991Gregory Gregoriadis
Versatility in both the structural characteristics of liposomes and their ability to accommodate a wide range of drugs has contributed to the design of appropriate formulations with optimal pharmacological actions.
Journal of Antimicrobial ChemotherapyAmphotericin B: an introduction
120 Citations1991David W. Warnock
There have been no controlled trials to support the use of drug combinations in human infections, apart from one report that the combination with flucytosine is superior to amphotericin B on its own in the treatment of cryptococcal meningitis.
Molecular PharmacologyMechanism of the selective toxicity of amphotericin B incorporated into liposomes.
118 Citations1987R. L. Juliano, Chris W.M. Grant +2 more
Analysis of several types of liposomes containing AMB at concentrations up to 5 mol %, using electron paramagnetic resonance and freeze fracture electron microscopy, shows that the drug is incorporated in the lipid bilayer but produces only modest disruptive effects on bilayer structure.
Antimicrobial Agents and ChemotherapyRole of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B
114 Citations1988Marcia L. Sokol-Anderson, James E. Sligh +4 more
The ergosterol deficiency in L and C probably impaired AmB binding to the cells, thereby lowering AmB effectiveness as measured by both cell membrane permeability and killing.
Drug Intelligence & Clinical PharmacyA Review of Complications of Amphotericin-B Therapy: Recommendations for Prevention and Management
112 Citations1980Michael S. Maddux, Steven L. Barriere
Various types of nephrotoxicity, thrombophlebitis, and anemia are described along with suggestions for their prevention and management, along with a commentary on allergic reactions.
The Journal of Infectious DiseasesInduction of Prostaglandin Synthesis as the Mechanism Responsible for the Chills and Fever Produced by Infusing Amphotericin B
104 Citations1987F Gigliotti, J. L. Shenep +2 more
It is postulate that the chills and fever produced by an infusion of amphotericin B are mediated through prostaglandin E2 synthesis, and ibuprofen is therapeutically useful in ameliorating the ch Chill reactions considered severe.
The Journal of Infectious DiseasesAn Emulsion Formulation of Amphotericin B Improves the Therapeutic Index When Treating Systemic Murine Candidiasis
104 Citations1988Richard Kirsh, Robert M. Goldstein +6 more
The efficacy and reduced toxicity of the amphotericin B emulsion are findings suggesting that the emulsion formulation is preferable to Fungizone.
BMJTrial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
104 Citations1992P. Chavanet, I. Garry +5 more
Clinical and renal toxicity of amphotericin are reduced when the drug is prepared in fat emulsion and its efficacy is similar to that of conventional amphoteric in a non-blind randomised controlled trial in HIV patients with candidiasis.
Antimicrobial Agents and ChemotherapyLiposomes as carriers of antimicrobial agents
102 Citations1987Gabriel Lopez‐Berestein
The biologic and pharmacologic attributes of liposomes have been exploited by several investigators for the delivery of antimicrobial agents and Liposome type, size, lipid composition, membrane fluidity, stability and charge, and ease of preparation are factors that must be considered when designing liposomal carriers.
Clinical Infectious DiseasesCurrent Role of Therapy with Amphotericin B
98 Citations1992Richard D. Meyer
The current role of amphotericin B therapy in these situations and the need for additional controlled, comparative clinical trials with azoles, liposomal amphotericIn B, and amphoteric in B complex are discussed.
Journal of Antimicrobial ChemotherapyLiposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients
96 Citations1991Rajesh Chopra, Scott C. Blair +4 more
Twenty patients undergoing myeloablative chemotherapy and/or bone marrow transplantation for haematological diseases with liposomal amphotericin (AmBisome) for proven or suspected aspergillosis are treated, finding recovery from probable fungal infection in this group of patients occurred when there was complete remission of underlying disease and recovery of neutrophil counts.
The Journal of Infectious DiseasesComparative Safety, Tolerance, and Pharmacokinetics of Amphotericin B Lipid Complex and Amphotericin B Desoxycholate in Healthy Male Volunteers
94 Citations1991V L Kan, John E. Bennett +5 more
ABLC yielded decreased amphotericin B levels and area under the serum concentration versus time curve relative to AB, which caused few acute adverse effects except for mild somnolence (drowsiness) in six volunteers.
Clinical Infectious DiseasesEmpiric Therapy with Amphotericin B in Febrile Granulocytopenic Patients
93 Citations1991Thomas J. Walsh, James Lee +9 more
Two randomized clinical trials demonstrated that the empiric administration of amphotericin B to persistently or recurrently febrile granulocytopenic patients decreased the frequency, morbidity, and mortality of invasive fungal infection.
The Journal of Infectious DiseasesTreatment of Experimental Invasive Aspergillosis with Novel Amphotericin B/Cholesterol-Sulfate Complexes
93 Citations1989Thomas F. Patterson, Peggy Miniter +4 more
The Amphotericin/cholesterol-sulfate complexes appear to be an improved means of amphotericin B delivery and may improve therapy for invasive aspergillosis.
Annals of Internal MedicineCardiopulmonary Toxicity after Liposomal Amphotericin B Infusion
85 Citations1991Stewart J. Levine, Thomas J. Walsh +4 more
Liposomal and lipid-complex drug delivery systems are being developed to enhance the therapeutic activity, decrease the toxicity, and provide site-specific delivery of high doses of amphotericin B in patients with high concentrations of these drugs.
Antimicrobial Agents and ChemotherapySingle-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers
81 Citations1991Steven W. Sanders, Kenneth N. Buchi +3 more
Twenty-three healthy volunteer subjects received a single dose of amphotericin B colloidal dispersion or placebo (4:2) in a double-blind, randomized, dose-escalating design, and a log-linear biexponential elimination phase was observed.
Clinical Infectious DiseasesFuture Directions of Antifungal Chemotherapy
74 Citations1992John R. Graybill
The 1990s will see consolidation of the uses of antifungals presently available, exploration of the use of much higher doses of amphotericin B (perhaps other polyenes as well in liposomal form), and perhaps theUse of azoles in combination as well as alone or sequentially in the form of polyene/azole antifundal therapy.
InfectionLiposomes as drug delivery system in the treatment of infectious diseases potential applications and clinical experience
65 Citations1988A. Coune
Clinical experience was obtained with two different liposomal preparations of amphotericin B in the treatment of systemic fungal diseases in cancer patients; these preparations were shown to be effective and very well-tolerated.
Clinical Infectious DiseasesLiposome-Encapsulated Amphotericin B: A Promising New Treatment for Disseminated Fungal Infections
60 Citations1988V. Wiebe, Michael W. DeGregorio
This liposome-encapsulated preparation appears to represent a promising new form of antifungal therapy that may reduce the dose-limiting toxicities of amphotericin B and improve treatment response.
Antimicrobial Agents and ChemotherapyIn vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations
56 Citations1990J. K. S. Chia, Edward J. McManus
It is found that the former preparation induced significantly more TNF than the latter preparation, and the in vitro data correlated with the results of rabbit pyrogen testing.
Antimicrobial Agents and ChemotherapyRandomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations
55 Citations1990Edward C. Oldfield, Paul Garst +3 more
There are no significant differences between patients in groups A and B in mean temperature, pulse, or systolic or diastolic blood pressure measured during the infusions of amphotericin B, but the onset of infusion-related toxicity occurs significantly earlier with a 1-h infusion.
Journal of Antimicrobial ChemotherapyOverview of the treatment of disseminated fungal infections
50 Citations1991R. J. Hay
There are too few comparative studies of drugs within the increasing number of antifungal agents which would provide a reliable basis for choice, and there remain a number of important problems, particularly the treatment of the patients with continuing immunosuppression and the emergence of antIFungal drug resistance.
Annals of Internal MedicineLiposomal Amphotericin B in the Treatment of Fungal Infections
40 Citations1986Gabriel Lopez‐Berestein
The successful development of drug carriers as tools to enhance the therapeutic index of known active drugs will depend on the appropriate selection of drug, drug carrier, and disease targe...
Clinical Pharmacology & TherapeuticsElimination of amphotericin B in impaired renal function
35 Citations1983Denis J. Morgan, Michael S. Ching +7 more
The influence of impaired renal function on the steady‐state plasma clearance of amphotericin B was determined in seven patients with creatinine clearances ranging from zero to normal, and steady-state plasma concentrations of total drug were lower in uremic patients than in patients with normal renal function.
Journal of Antimicrobial ChemotherapyEfficacies of ampbotericin B lipid complex (ABLC) and conventional amphotericin B against marine coccidioidomycosis
34 Citations1992Karl V. Clemons, David A. Stevans
At equal non-toxic amphotericin B doses, conventional amphotericIn B was more effective than ABLC in reducing cfu in infected organs in murine models of acute systemic coccidioidomycosis.
The Journal of Infectious DiseasesSafety and Efficacy of Liposomal Amphotericin B in Treating AIDS-Associated Disseminated Cryptococcosis
34 Citations1991Dirk Schürmann, B. de Matos Marques +4 more
Journal of Antimicrobial ChemotherapyIn-vitro effects of liposome-encapsulated amphotericin B (AmBisome) and amphotericin B-deoxycholate (Fungizone) on the phagocytic and candidacidal function of human polymorphonudear leucocytes
23 Citations1992C.J. Pallister, Elizabeth M. Johnson +3 more
The results suggest that much higher concentrations of liposomal amphotericin B (AmBisome) are required to produce deleterious effects on neutrophil phagocytic function than with the conventional formulation of the drug.
Antimicrobial Agents and ChemotherapySensitivity of Candida albicans to amphotericin B administered as single or fractionated doses
13 Citations1986Marcia L. Sokol-Anderson, J Brajtburg +1 more
Increased catalase activity in C. albicans cells was induced after exposure to fractionated doses of AmB; this increase may have contributed to the greater resistance of cells to AmB used according to this schedule.
Journal of Liposome ResearchArguments for a New Formulation of Liposomal Amphotericin B: An Historical Perspective
4 Citations1990G. B. Mackaness
Why liposomes as vehicles in which to administer amphotericin B have the potential to redress this agent's principal deficiency is explained.